An Efficacy and Safety Study of Fremanezumab in Adults With Migraine (FOCUS)
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
A PHASE3 clinical study on Migraine Prophylaxis, this trial is completed. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 23 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
23 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 18 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2020 — May 2020 [monthly]
Completed PHASE3
-
Feb 2020 — Apr 2020 [monthly]
Completed PHASE3
-
Dec 2019 — Feb 2020 [monthly]
Completed PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Completed PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .